Introduction
============

In 1977, Frederick Sanger developed a new method for DNA sequencing based on the chain termination method, where nucleotides in a single-stranded DNA molecules are determined by complementary synthesis of polynucleotide chains, based on the selective incorporation of chain-terminating dideoxynucleotides driven by the DNA polymerase enzyme ^[@ref-1]^. For this method, Sanger was awarded in 1980 with a second Nobel Prize in Chemistry, and nowadays this method is still known as the Sanger method of DNA sequencing, becoming a standard method in clinical genetics. The present opinion article wants to remark that, targeted SSM is still effective in specific clinical scenarios at a lower cost as a diagnostic method compared to new technologies for sequencing, one example is the detection of Andersen-Tawil syndrome (ATS).

Next-generation sequencing: available for everyone?
===================================================

Next-generation sequencing (NGS) technology, also known as massive parallel, high throughput or deep sequencing, is gradually replacing the traditional SSM as the first choice method for screening mutations in genetic cardiovascular diseases ^[@ref-2]^.

The genetic heterogeneity in long QT ^[@ref-3]^ and Brugada syndromes ^[@ref-4]^ has made this new genetic testing approach mandatory. The advantages of NGS versus the SSM in cases of genetic heterogeneity are undeniable, but NGS is still expensive and unaffordable for developing countries. The SSM remains the gold standard for sequencing short fragments of DNA (\<1000 bases), previously amplified by PCR.

Andersen-Tawil Syndrome: a rare disease
=======================================

ATS, also named Long QT syndrome type 7, is described in the Online Mendelian Inheritance in Man database ( [OMIM](https://www.omim.org/)) as a multisystem autosomal dominant channelopathy syndrome caused by a heterozygous mutation in the *KCNJ2* gene (OMIM Entry - \*600681) on chromosome 17q24.3. Periodic paralysis, ventricular arrhythmia, and distinctive dysmorphic features characterize it. Until 2015, the only gene thought to be affected was the potassium voltage-gated channel subfamily J member 2 ^[@ref-5]^ (the *KCNJ2* gene), which encodes the alpha subunit protein of the Kir2.1 channel composed of tetramers ^[@ref-6]^. Mutations in this gene have been reported in 60% of clinically suspected cases (which are classified as ATS type 1) ^[@ref-7]^. Less than 200 cases with the *KCNJ2* gene affected have been described worldwide since the discovery of the first mutations in 2001 ^[@ref-8],\ [@ref-9]^. In 2014, a novel variant (c.472A\>G; p.Thr158Ala) in a second gene, *KCNJ5*, was associated with ATS in one Japanese patient taken from a cohort of 21 patients that had previously been screened negative for mutations in *KCNJ2*. The *KCNJ5* gene protein (potassium channel Kir 3.4 protein) has an interaction with the *KCNJ2* protein that leads to a dominant negative effect in the channel formed, related to the ATS phenotype ^[@ref-10]^. No additional cases of *KCNJ5* mutations in independent series of ATS patients have been reported; the frequency of *KCNJ5* mutations in ATS has to be determined in the future. With the widespread use of NGS, it is possible that in the next years we could discover new genes that explain part of the genetic heterogeneity observed in ATS, clarifying some of the 40% of clinically suspected negative cases that do not have a mutation in *KCNJ2* (nowadays classified as ATS type 2) ^[@ref-11]^.

A special gene: *KCNJ2*
=======================

The *KCNJ2* gene has particular structural characteristics that makes it attractive for direct SSM, such as a relatively short sequence of 17,510 base pairs (bp), and a coding region with near to 5,000 bp with two exons (exon 1=166 bp and exon 2=5220 bp). Also, half of the mutations are located in the C-terminal cytosolic domain, and have a mutational hotspot in the residue Arg218; as we have addressed before, this gene explains the phenotype in 60% of ATS cases, fulfilling the clinical criteria.

ATS in mestizo populations: the first description of ATS in the Mexican population
==================================================================================

Fifteen years have passed since the first family with ATS in a Mexican population was reported by Canun *et al*. ^[@ref-12]^ Recently, a second proband was diagnosed in a different Mexican family, finding the mutation p.Arg218Trp in *KCNJ2* ^[@ref-13]^.

Multidisciplinary approach: a productive collaboration
======================================================

A multidisciplinary approach is extremely useful to study suspicious cases of hereditary sudden death syndrome. For ATS, the team must include a cardiologist, a neurologist and a clinical geneticist. It is very important that each of these physicians had expertise in the evaluation of subjects with sudden cardiac death syndrome. After a common agreement on suspicion of ATS, the whole coding region and intron boundaries of the non-coding region in *KCNJ2* could be sequenced with the SSM ^[@ref-14]^.

Clinical ATS data that needs to be considered
=============================================

Phenotypically, Canun *et al* ^[@ref-11]^ suggested that recognition of facial and limb dysmorphism (broad forehead, bushy eyebrows, small eyes, bulbous nose, malar and mandibular hypoplasia, crowded teeth, clinodactyly in the 5 ^th^ finger and cutaneous syndactyly in 2--3 toes) associated with ATS could help establish a correct ATS diagnosis. We believe that it is important that all cardiologists dealing with subjects with ventricular arrhythmias, specifically frequent ventricular premature beats in bigeminy, are aware of such distinctive phenotypic characteristics and also search for muscular disorders (weakness in limbs or periodic paralysis).

Sanger sequencing is still a useful method
==========================================

The SSM is nearly 40 years old, and it remains a useful molecular tool for genetic testing. It has its limitations because it is time-consuming, has limited use for long DNA fragments and is unable to detect sequences out of the region contemplated. We consider using "directed" SSM as first-line approach for diagnosis of suspected cases of ATS in places where NGS is not an option for genetic testing (due to low availability or high cost).

The authors are grateful to their patients.
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The opinion article by Totomoch-Serra and colleagues suggests that a "targeted" Sanger Sequencing Method (SSM) is an appropriate first-line approach to diagnose Andersen-Tawil syndrome (ATS). Although Next-Generation Sequencing (NGS) technology, especially in cases of genetic heterogeneity, is gradually replacing the traditional SSM as the method of choice for genetic testing, its high cost and unavailability often preclude its routine use, particularly in developing countries. The authors maintain that for conditions that require sequencing of short fragments of DNA (\<1000 bases), previously amplified by PCR, SSM remains the gold standard. In ATS, where 60% of the reported cases involve mutations of the *KCNJ2* gene (that codes for the Kir2.1 channel protein) exhibiting autosomal dominant Mendelian inheritance, half the mutations are located in the C-terminal cytosolic domain with a hotspot at Arg218 (ATS type 1). Characteristic developmental abnormalities coupled to specific ventricular arrhythmias and/or muscular disorders can identify ATS patients who could then undergo SSM to identify the putative causative mutations in KCNJ2 with a potential 60% success. NGS could then be applied if the patient falls within the 40% of the cases that are not due to KCNJ2 (ATS type 2) with the hope to discover additional genes responsible for the disease and determine their frequency of occurrence. The opinion expressed by the authors is reasonable and advisable to physicians especially in cases where cost and access to NGS are problematic. Yet, it is likely a matter of time before cost and access to NGS improve and limit the choice of SSM for genetic testing. SSM has certainly served us well for the past 40 years and continues to serve us well in cases like ATS type 1 but it is inevitable that NGS will eventually make it obsolete. Until then, the authors make their case convincingly through this opinion article.
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This opinion article by Totomoch-Serra *et al*.refers to the usefulness of directed sequencing of *KCNJ2* by Sanger method for molecular diagnosis of Andersen-Tawil syndrome (ATS), a rare QT long syndrome associating ventricular arrhythmias, prominent U wave, dysmorphic facial or skeletal features and periodic paralysis.

Sanger sequencing remains a useful method for directed sequencing of specific clinical syndromes with low genetic heterogeneity as ATS, especially in places where NGS is not accessible. In another hand, NGS is particularly useful and cost effective in inherited cardiomyopathies or channelopathies associated with high genetic heterogeneity (like dilated cardiomyopathy) or caused by mutations in larges genes (as *RYR2* or *TTN*) where Sanger sequencing remains a long and expensive process. NGS can also be useful at second level when directed molecular diagnosis with Sanger method is negative.

In case where ATS is suspected, the approach described by the authors with directed sanger sequencing at first line followed by NGS in case of negative screening is a cost-effective approach for ATS molecular diagnosis.

I would only suggest describing in more details the clinical features (including symptoms or family history) suggestive of ATS diagnosis that should direct to *KCNJ2* sequencing at first line. Addition of a typical ECG could also be useful for the reader. Comparison of costs between NGS and Sanger sequencing could also be interesting.
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It is a well written manuscript focused on use of Sanger technology in genetic diagnosis. Currently, despite to NGS technology allows a cost-effective analysis of hundreds genes in a reduced time, Sanger sequencing remains as gold standard for validation of variants identified using NGS, segregation of variants in family members, and analysis of small genes, such as KCNJ2.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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